Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product

Enrolling by invitation

Conditions studied: Diabetic Kidney Disease, Chronic Kidney Disease

In brief

The purpose of this study is to evaluate the long-term safety, efficacy, and durability in participants with chronic kidney disease (CKD) who received up to four REACT injections, delivered percutaneously into either the same or bilateral kidneys in previous studies.

Key facts

Study ID

NCT06790498

Run by

Prokidney

People needed

50

Starts

2023-11-23

Expected to finish

2030-08-31

Last updated by the study team

2025-01-24

Who can join

Age: 30 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The participant must have received REACT in a previous trial (REGEN-006, REGEN- 007, and REGEN-015) for the treatment of chronic kidney disease and completed an end of study visit in their previous trial per protocol.
• The participant is willing and able to cooperate with all aspects of the protocol.
• The participant is willing and able to provide signed informed consent.

You may not qualify if…

• Participant did not receive REACT in a previous trial for the treatment of chronic kidney disease

Where it is running

• Boise Kidney & Hypertension Institute — Meridian, Idaho, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.